For Q2, Supernus Pharmaceuticals (SUPN -4.6%) reported revenue of $126.73M (+21.0% Y/Y) missed consensus by $5.27M.
GAAP EPS of $0.65 (vs. $0.61 in year ago quarter) beats consensus by $0.16.
As of June 30, 2020, cash and equivalents stood at $210.98M compared to $181.38M as of December 31, 2019.
In early April, the company entered into a development and option agreement with Navitor Pharmaceuticals for conducting a Phase II clinical program for NV-5138 (SPN-820) in treatment-resistant depression.
In early June, Supernus completed its acquisition of all of the outstanding equity of privately-held biopharmaceutical company, USWM Enterprises for $297.2M in cash thereby acquiring the right to further develop and commercialize APOKYN, XADAGO and the Apomorphine Infusion Pump in the U.S. and MYOBLOC worldwide for treating Parkinson’s disease.
Previously: Supernus Pharmaceuticals EPS beats by $0.16, misses on revenue (Aug 18)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.